|
Jun 22
|
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
|
|
Jun 20
|
Recent 5.2% pullback isn't enough to hurt long-term MannKind (NASDAQ:MNKD) shareholders, they're still up 327% over 5 years
|
|
May 13
|
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
|
|
May 10
|
MannKind First Quarter 2024 Earnings: Beats Expectations
|
|
May 10
|
MannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ...
|
|
May 9
|
MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's Why
|
|
May 9
|
MannKind (MNKD) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
|
|
May 8
|
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
|
|
May 8
|
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
|
|
May 6
|
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
|
|
May 1
|
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
|
|
Apr 30
|
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
|
|
Apr 29
|
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
|
|
Apr 3
|
MannKind Repays Certain Debt Obligations
|
|
Apr 1
|
MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns
|
|
Mar 29
|
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
|
|
Mar 26
|
MannKind Announces CFO Transition
|
|
Mar 25
|
Jim Cramer Says You Should Avoid These 11 Stocks
|